People with chronic liver disease and high risk of liver cancer who have hepatitis B, hepatitis C, cirrhosis, metabolic-associated fatty liver disease (MAFLD) and moderate liver fibrosis.
Conditions
Interventions
Case series :none
Sponsors
Affiliated Hospital of Guangdong Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Patients diagnosed with chronic hepatitis B through in-hospital or out-of-hospital channels: Hepatitis B surface antigen continues to be positive for 6 months or more; 2. Patients diagnosed with chronic hepatitis C through in-hospital or out-of-hospital channels; 3. For patients diagnosed with cirrhosis either in-hospital or outpatient, the presence of cirrhosis is indicated by abnormalities in the following test indicators (meeting at least one of the following criteria): (1) Liver biopsy showing cirrhosis (Ishak score >= 5 or Metavir score = 4); (2) Liver stiffness measurement (LSM) using FibroScan ® (Echosens™, Paris, France) >= 12.0 kPa with normal serum total bilirubin (TB) and ALT = 17.0 kPa with normal TB and ALT = 2.0; (5) FIB-4 index >= 3.25. 4. For patients diagnosed with metabolic-associated fatty liver disease (MAFLD) and moderate liver fibrosis, either in-hospital or outpatient, the specific criteria are as follows: a liver fibrosis score of F3 or above according to liver transient elastography, which corresponds to a liver stiffness measurement (LSM) value of =10 kPa using FibroScan® or the corresponding threshold for FibroTouch® [24]; or a non-invasive liver fibrosis index of FIB-4 > 3.25; or NFS > 0.67; or APRI > 1. (1) Metabolic-associated fatty liver disease is defined by controlled attenuation parameter (CAP) from transient elastography, or similar parameters, or liver biopsy diagnosing >5% fat accumulation, accompanied by one of the following three conditions: overweight/obesity (BMI > 23 kg/m²), type 2 diabetes, or metabolic dysfunction. 5. For patients diagnosed with metabolic-associated fatty liver disease (MAFLD) complicated with abnormal glucose metabolism through inpatient or outpatient services: (1) The definition of metabolic-associated fatty liver disease is the same as in d) (2) Abnormal glucose metabolism is defined as type 2 diabetes or prediabetes, which is indicated by a fasting plasma glucose level of 5.6-6.9 mmol/L, or a 2-hour postprandial plasma glucose level of 7.8-11.0 mmol/L, or a glycated hemoglobin level of 5.7%-6.4%. 6. Subjects with a family history of liver cancer in first-degree relatives (first-degree relatives: parents, children, siblings);
Exclusion criteria
Exclusion criteria: 1. Age 75 years old; 2. Those with severe mental illness or cognitive impairment; 3. According to the doctor’s judgment, the possibility of selection is low (including inability to understand project requirements, poor compliance, frailty, and inability to Ensure that the plan can be implemented as required, etc.), or the doctor believes that there are other factors that are not suitable for this project.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Liver cancer screening; | — |
Countries
China
Contacts
Public ContactLiu Bin
Affiliated Hospital of Guangdong Medical University
Outcome results
None listed